CN108079035A - A kind of hypoglycemic anti-inflammatory nutrient solution and preparation method thereof - Google Patents
A kind of hypoglycemic anti-inflammatory nutrient solution and preparation method thereof Download PDFInfo
- Publication number
- CN108079035A CN108079035A CN201810131524.2A CN201810131524A CN108079035A CN 108079035 A CN108079035 A CN 108079035A CN 201810131524 A CN201810131524 A CN 201810131524A CN 108079035 A CN108079035 A CN 108079035A
- Authority
- CN
- China
- Prior art keywords
- nutrient solution
- american ginseng
- solution
- inflammatory
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 27
- 230000002218 hypoglycaemic effect Effects 0.000 title claims abstract description 25
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000002253 acid Substances 0.000 claims abstract description 17
- 241000894006 Bacteria Species 0.000 claims abstract description 14
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 14
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 14
- 241000186660 Lactobacillus Species 0.000 claims abstract description 11
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 11
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 11
- 239000011707 mineral Substances 0.000 claims abstract description 11
- 235000010755 mineral Nutrition 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 239000011573 trace mineral Substances 0.000 claims abstract description 7
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 7
- 241000186046 Actinomyces Species 0.000 claims abstract description 4
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 4
- 241000235342 Saccharomycetes Species 0.000 claims abstract description 4
- 230000000243 photosynthetic effect Effects 0.000 claims abstract description 4
- 239000002893 slag Substances 0.000 claims abstract description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 239000002609 medium Substances 0.000 claims description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 239000005864 Sulphur Substances 0.000 claims description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 239000010941 cobalt Substances 0.000 claims description 3
- 229910017052 cobalt Inorganic materials 0.000 claims description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000011733 molybdenum Substances 0.000 claims description 3
- 229910052750 molybdenum Inorganic materials 0.000 claims description 3
- 229910052759 nickel Inorganic materials 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 229910052710 silicon Inorganic materials 0.000 claims description 3
- 239000010703 silicon Substances 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 229910052718 tin Inorganic materials 0.000 claims description 3
- 229910052720 vanadium Inorganic materials 0.000 claims description 3
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 abstract description 5
- 230000004913 activation Effects 0.000 abstract description 3
- 210000004153 islets of langerhan Anatomy 0.000 abstract description 3
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 28
- 239000003814 drug Substances 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 108010075254 C-Peptide Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 206010066786 Diabetic keratopathy Diseases 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of hypoglycemic anti-inflammatory nutrient solution and preparation method thereof, first American Ginseng is placed in 100 DEG C of water impregnate 36 it is small when after remove slag, allotment obtains concentration as 35% American Ginseng extracting solution；Actinomyces, photosynthetic bacteria, lactobacillus, saccharomycete, Bifidobacterium are put into acid conventional medium and cultivated, obtains concentration as 40% acid culture bacterium solution；The acid culture bacterium solution 1% -2% in the step 2, the American Ginseng extracting solution 44% -50% in the step 1 are taken, adds the water mixing of mineral salt 1.01% -2.2% and surplus；Under 20 DEG C of environment, concentration is added in the mixed liquor obtained in the step 3 as 40% lactobacillus mixed liquor 0.1% -0.5%, stand 120 148 it is small when after obtain final hypoglycemic anti-inflammatory nutrient solution.The present invention is capable of providing a kind of mineral trace element proportioning equalize, the physiological activation for promoting function of human body tissue, improves autonomous hypoglycemic anti-inflammatory nutrient solution repaired and can eliminate insulitis of metabolism quality, strengthen immunity and damaged islet cells and preparation method thereof.
Description
Technical field
The present invention relates to nutrition liquid preparing process more particularly to a kind of hypoglycemic anti-inflammatory nutrient solution and preparation method thereof.
Background technology
At present for treating the only hypoglycemic medicine of diabetes, and no elimination insulitis drug, exist single
One property, passivity and limitation.Existing hypoglycemic medicine is mainly to block human body to the absorption of glucose to reach the mesh of hypoglycemic
, and human body must actually have enough glucose to ensure the storage of inose and liver glycogen, and human body not so will be made long-term
The normal function of internal internal organs can be influenced in fatigue dress state.And hypoglycemic medicine be with side effect and significant limitation,
Particularly diet can trigger the malnutrition of human body, reduce immunity, be unable to reach the effect of good treatment and rehabilitation, there are no
Method eliminates pancreas islet nonspecific inflammation.
The content of the invention
A kind of mineral trace element proportioning equalize the invention aims to overcome the deficiencies in the prior art is provided, is promoted
Into the physiological activation of function of human body tissue, the autonomous reparation for being metabolized quality, strengthen immunity and damaged islet cells and energy are improved
Eliminate hypoglycemic anti-inflammatory nutrient solution of insulitis and preparation method thereof.
In order to achieve the above objectives, present invention employs following technical solutions.
A kind of hypoglycemic anti-inflammatory nutrient solution, the weight percentages of components specifically included are：Concentration is 35% American Ginseng extracting solution
44% -50%, concentration is that 40% acid bacterium solution 1% -2%, minerals 1.01% -2.2%, the concentration of cultivating is 40% lactobacillus mixed liquor
0.1% -0.5%, surplus is water.
A kind of preparation method of hypoglycemic anti-inflammatory nutrient solution, specifically includes following steps：
Step 1：First by American Ginseng be placed in 100 DEG C of water impregnate 36 it is small when after remove slag, allotment obtain concentration for 35% west
American ginseng extracting solution；
Step 2：Actinomyces, photosynthetic bacteria, lactobacillus, saccharomycete, Bifidobacterium are put into acid conventional medium and cultivated, is obtained
Concentration is 40% acid culture bacterium solution；
Step 3：Take the acid culture bacterium solution 1%-2% in the step 2, the American Ginseng extracting solution 44% in the step 1-
50%, add the water mixing of mineral salt 1.01% -2.2% and surplus；
Step 4：Under 20 DEG C of environment, concentration is added in the mixed liquor obtained in the step 3 and is mixed for 40% lactobacillus
Liquid 0.1% -0.5%, stand 120-148 it is small when after obtain final hypoglycemic anti-inflammatory nutrient solution.
As a further improvement on the present invention, the acid conventional medium is to add in alimentary acetic acid in conventional medium,
Its ratio be 6:1.
As a further improvement on the present invention, the mineral salt include trace element magnesium, sodium, phosphorus, sulphur, chlorine, iron, copper,
Iodine, cobalt, molybdenum, nickel, fluorine, vanadium, tin, silicon.
Due to the utilization of above-mentioned technical proposal, advantageous effects that technical solution of the present invention is brought：Existing antidiabetic drug
If owner blocks human body to the absorption of glucose to achieve the purpose that hypoglycemic, and human body must actually have enough grapes
For sugar to ensure the storage of inose and liver glycogen, human body not so will be made, which to be chronically at fatigue dress state, can influence the normal work(of internal internal organs
Can, and hypoglycemic medicine is to trigger the malnutrition of human body with side effect and significant limitation, particularly diet, is reduced
Immunity is unable to reach the effect of good treatment and rehabilitation, and it is even more impossible to eliminate pancreas islet nonspecific inflammation；By this technology side
The nutrient solution that case prepares, which has, is rationally balancedly blended together nutrient for plants with mine trace element, by people
Body supplements the compositions such as the mine trace element of the protein of complete equilibrium, amino acid, polysaccharide, vitamin and ionic state comprehensively,
Promote the physiological activation of function of human body tissue, improve metabolism quality, the autonomous reparation of strengthen immunity and damaged islet cells disappears
Except insulitis.
Specific embodiment
With reference to specific embodiment, the present invention is described in further detail.
First, specific embodiment is prepared：
（1）3 kilograms of American Ginseng is impregnated in 100 degree of 12 kilograms of water 36 it is small when, remove slag to obtain 10 kilograms of extracting solutions（Concentration
35%）；
（2）Actinomyces, photosynthetic bacteria, lactobacillus, saccharomycete, Bifidobacterium are put into acid conventional medium and cultivated, it is acid normal
It is to add in alimentary acetic acid in conventional medium to advise culture medium, and its ratio be 6:1, take 1 kilogram of bacterium solution（Concentration 40%）；
（3）Acid culture bacterium solution is taken to be mixed with American Ginseng extracting solution, is added containing the necessary micro- mineral salt 10 of human body
Gram, mineral salt contains trace element：Magnesium, sodium, phosphorus, sulphur, chlorine, iron, copper, iodine, cobalt, molybdenum, nickel, fluorine, vanadium, tin, silicon, add water purification
To 99.9 kilograms；
（4）Add in 100 grams of the mixed liquor of lactobacillus（Concentration 40%）The hypoglycemic anti-inflammatory of double centner is obtained when standing 120 is small after mixing
Nutrient solution, sterilization packaging.
2nd, the specifically used and example effects of hypoglycemic anti-inflammatory nutrient solution
The instructions of taking of the hypoglycemic anti-inflammatory nutrient solution, it is different for different diabetics its taking dose, take when
Between length it is also different.It is specific as follows：
1st, the diabetic that has just detected simultaneously never takes Chinese and Western medicine, and C peptide levels are normal in blood, and instructions of taking is：Often
Its taking dose is 150ml to 300ml, in three times, each 50ml to 100ml.The cycle is taken as four months i.e. 120 day.Between not
Disconnection, which continues, takes 2 cycles i.e. 240 days, and clinic is controlled Yu and led as more than 90%.
2nd, suffer from diabetes 1-3, take that C peptide levels in 1 to 2 kind of Western medicine and blood are normal, and instructions of taking is：It takes daily
Dosage is 120ml, totally four times：In the morning, afternoon and evening it is each before the meal once, added before sleeping once, each 30ml.Uninterruptedly continuously took for 3 week
Phase i.e. 360 day or so, clinic control Yu and lead about 75%.
3rd, diabetes 5 years or more are suffered from, two or more Chinese and Western medicine is taken in treatment（Containing insulin injection）, and C peptide levels are less than just
Ordinary water is put down, and with different degrees of various diabetic keratopathy syndrome phenomenons, taking dose is daily 120ml, in four times, in the morning, afternoon and evening
Each before the meal once to be added before sleeping once, each dosage is 30ml.It is uninterrupted to take about 3 cycle i.e. 360 day or so, eliminate sugar
It is 95% or so that it is efficient, which to urinate myelodysplastic syndromes,.About 60% or so crowd can realize rehabilitation, and about 85% or so crowd, which can realize to subtract, to stop
Medicine.To suffering from diabetes 5 years or more, but do not occur the patient of diabetic keratopathy syndrome, more than 95% diabetic syndrome does not occur.
Case 1：Certain is gone into business, man, 35 years old, hospital just detected diabetes, and I types, C peptide levels are normal, and blood glucose target is
8.5mmol/L（It is normally 6.1mmol/L/following）, triglycerides 5.8mmol/L（It is normally below 1.8mmol/L）, clothes
After this technology nutrient solution 120 days, blood glucose target is below 6.1mmol/L, and triglycerides is 2.0 mmol/L.It takes 240 days
Afterwards, blood glucose target is below 6.0mmol/L, and triglycerides 1.56.0mmol/L, binomial is stable normal, no relapse.
Case 2：Chen, man, 55 years old, 5 years diabetes ages or more, II types.C peptide levels are normal, and blood glucose target is
11.76mmol/L（It is normally below 6.1mmol/L）, triglycerides 4.8mmol/L（It is normally below 1.8mmol/L）, always
Bilirubin 25.6mmo l/L（It is normally 5.0-19.0mmol/L）, indirect bilirubin 19.2mmol/L（It is normally 0.1-
17.0mmol/L）.Clinical treatment takes melbine, daily 6.After taking this technology nutrient solution 90 days, blood glucose target is
5.70mmol/L, triglycerides are 2.18 mmol/L.Total bilirubin is 22.0mmol/L, indirect bilirubin 18.0mmol/L.Stop
It takes and continues to take this technology nutrient solution after melbine to 240 days, more than index is normal, and no relapse.
Case 3：Zou, man, 51 years old, 12 years diabetes ages, II types.C peptide levels are less than normal level（It is normal for 0.4 ±
0.2 nmol/L）, blood glucose target 11.17mmol/L, clinical treatment takes sulfonylureas and daily 13 of biguanide drug, in additional
Medicine decoction, and with diabetes coronary heart disease, failing depending on rate, impotence, weakness of limbs, wound not syndromes such as more.Take this
After technical nutrient liquid, vision restoration is normal within 60 days, and 90 days impotence, wounds are not more and the symptom complexs such as weakness of limbs disappear.Continue
It takes to after 120 days, disables Chinese medicine, only take melbine 4 daily.Blood glucose is 6.8mmol/L or so.Continue to take this technology
Nutrient solution disappears to all Chinese and Western medicines, diabetes coronary heart disease symptom after 240 days, is withdrawn.Blood glucose is 6.0 mmol/L or so.Clothes
With this technology nutrient solution to after 360 days, physical rehabilitation, recurrence that so far there are no.
It the above is only the concrete application example of the present invention, protection scope of the present invention be not limited in any way.All uses
Equivalent transformation or equivalent replacement and the technical solution formed, all fall within rights protection scope of the present invention.
Claims (5)
1. a kind of hypoglycemic anti-inflammatory nutrient solution, which is characterized in that the weight percentages of components specifically included is：American Ginseng extracting solution
44% -50%, acid culture bacterium solution 1% -2%, minerals 1.01% -2.2%, lactobacillus mixed liquor 0.1% -0.5%, surplus are
Water.
2. a kind of hypoglycemic anti-inflammatory nutrient solution according to claim 1, it is characterised in that：The concentration of the American Ginseng extracting solution
For 35%, the acid culture bacterial concentration is 40%, and the lactobacillus mixed liquor is 40%.
3. a kind of preparation method of hypoglycemic anti-inflammatory nutrient solution, which is characterized in that specifically include following steps：
Step 1：First by American Ginseng be placed in 100 DEG C of water impregnate 36 it is small when after remove slag, allotment obtain concentration for 35% west
American ginseng extracting solution；
Step 2：Actinomyces, photosynthetic bacteria, lactobacillus, saccharomycete, Bifidobacterium are put into acid conventional medium and cultivated, is obtained
Concentration is 40% acid culture bacterium solution；
Step 3：Take the acid culture bacterium solution 1%-2% in the step 2, the American Ginseng extracting solution 44% in the step 1-
50%, add the water mixing of mineral salt 1.01% -2.2% and surplus；
Step 4：Under 20 DEG C of environment, concentration is added in the mixed liquor obtained in the step 3 and is mixed for 40% lactobacillus
Liquid 0.1% -0.5%, stand 120-148 it is small when after obtain final hypoglycemic anti-inflammatory nutrient solution.
4. a kind of preparation method of hypoglycemic anti-inflammatory nutrient solution according to claim 3, it is characterised in that：It is described acid conventional
Culture medium is to add in alimentary acetic acid in conventional medium, and its ratio be 6:1.
5. a kind of preparation method of hypoglycemic anti-inflammatory nutrient solution according to claim 3, it is characterised in that：The mineral salt bag
Contain trace element magnesium, sodium, phosphorus, sulphur, chlorine, iron, copper, iodine, cobalt, molybdenum, nickel, fluorine, vanadium, tin, silicon.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810131524.2A CN108079035A (en) | 2018-02-09 | 2018-02-09 | A kind of hypoglycemic anti-inflammatory nutrient solution and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810131524.2A CN108079035A (en) | 2018-02-09 | 2018-02-09 | A kind of hypoglycemic anti-inflammatory nutrient solution and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108079035A true CN108079035A (en) | 2018-05-29 |
Family
ID=62193860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810131524.2A Pending CN108079035A (en) | 2018-02-09 | 2018-02-09 | A kind of hypoglycemic anti-inflammatory nutrient solution and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108079035A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108524592A (en) * | 2018-07-11 | 2018-09-14 | 昆山绿清婷生物科技有限公司 | A kind of prevention diabetic syndrome nutrient solution |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1526419A (en) * | 2003-03-06 | 2004-09-08 | 陈根龙 | Blood sugar and blood fat reducing composite microbial mineral nutrient liquid and its prepn process |
| US6852707B1 (en) * | 1998-12-10 | 2005-02-08 | Suntory Limited | Remedies for hyperammonemia |
| CN106819732A (en) * | 2016-12-25 | 2017-06-13 | 山东奥博森医药科技有限公司 | It is a kind of to prevent and treat fermented beverage of diabetes and preparation method thereof |
-
2018
- 2018-02-09 CN CN201810131524.2A patent/CN108079035A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6852707B1 (en) * | 1998-12-10 | 2005-02-08 | Suntory Limited | Remedies for hyperammonemia |
| CN1526419A (en) * | 2003-03-06 | 2004-09-08 | 陈根龙 | Blood sugar and blood fat reducing composite microbial mineral nutrient liquid and its prepn process |
| CN106819732A (en) * | 2016-12-25 | 2017-06-13 | 山东奥博森医药科技有限公司 | It is a kind of to prevent and treat fermented beverage of diabetes and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 季宇彬: "《抗癌中药药理与应用》", 28 February 1999, 黑龙江科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108524592A (en) * | 2018-07-11 | 2018-09-14 | 昆山绿清婷生物科技有限公司 | A kind of prevention diabetic syndrome nutrient solution |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101947234A (en) | Preparation method for preparation containing glucosamine and application thereof | |
| CN102526103B (en) | Multi-trace element injection and preparation method thereof | |
| CN101947240A (en) | Mixed sugar electrolyte drug composite injection | |
| CN103385889B (en) | Carbohydrate and electrolyte mixed injection and preparation method thereof | |
| CN101978965B (en) | Use of medicine in treating diabetes | |
| CN102125196A (en) | Bee product formulation | |
| CN108079035A (en) | A kind of hypoglycemic anti-inflammatory nutrient solution and preparation method thereof | |
| CN103110640B (en) | Pharmaceutical composition of injection ceftizoxime sodium and compound amino acid injection | |
| CN109481459B (en) | Compound electrolyte glucose injection and preparation method thereof | |
| CN100544734C (en) | Compound fructose electrolyte injection and preparation method thereof | |
| CN101642476A (en) | Production method of organic selenium ganoderma lucidum spore powder | |
| RU2400251C1 (en) | Method of treating chronic kidney disease in predialytic and dialytic periods and medication for its realisation | |
| CN108524592A (en) | A kind of prevention diabetic syndrome nutrient solution | |
| CN111297821A (en) | Coenzyme Q10 capsule and preparation process thereof | |
| CN103463094B (en) | Medicine composition of cefpiramide sodium and infant compound amino acid injection (19AA-I) | |
| CN104884066A (en) | Amylase-activity-inhibiting composition containing chito-oligosaccharide | |
| CN107595829B (en) | A kind of composition for preventing and treating renal osteodystrophy | |
| CN1099871C (en) | Shuanggan injection and preparation process thereof | |
| CN107233307A (en) | A kind of ibuprofen injection and preparation method thereof | |
| CN1234360C (en) | Complementary gain pain-killing medicine | |
| CN101972273B (en) | Application of medicine in preparing medicines for treating diabetes mellitus | |
| CN116407535A (en) | Application of compound amino acid preparation in preparation of hypoglycemic drugs | |
| CN103446056B (en) | Pharmaceutical composition containing ceftizoxime sodium and pediatric compound amino acid injection (19AA-I) | |
| CN113082199A (en) | Pharmaceutical composition for treating nephropathy and preparation method thereof | |
| CN113170898A (en) | Health-care composition assisting in reducing blood sugar and blood fat and health-care product thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180529 |